NUTRA PHARMA CORP. (OTCMKTS:NPHC) Files An 8-K Regulation FD DisclosureITEM 7.01Regulation FD Disclosure.
On September 28, 2018, Nutra Pharma Corp. (the “Company”) issued a press release regarding the lawsuit described in Item 8.01 of this Current Report on Form 8-K; a copy of such press release is furnished as Exhibit99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference. The information included in this Item 7.01 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
ITEM 8.01Other Events.
On September 28, 2018, the United States Securities and Exchange Commission filed a lawsuit in the United States District Court for the Eastern District of New York against the Company and its CEO and Chairman Rik J. Deitsch, and a consultant to the company, Sean McManus, alleging violations of the Securities Act, the Exchange Act and rules promulgated thereunder.
ITEM 9.01Financial Statements and Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release of the Company dated September 28, 2018 |
NUTRA PHARMA CORP ExhibitEX-99.1 2 exh99_01.htm PRESS RELEASE DATED SEPTEMBER 28,…To view the full exhibit click here
About NUTRA PHARMA CORP. (OTCMKTS:NPHC)
Nutra Pharma Corp. is a biopharmaceutical company. The Company is engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies, as well as homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, autoimmune and infectious diseases. The Company’s subsidiary and drug discovery arm, ReceptoPharm, Inc. (ReceptoPharm), carries its homeopathic and drug discovery research and clinical development and has developed homeopathic drugs for the treatment of pain: Cobroxin, an over-the-counter pain reliever designed to treat moderate to severe (Stage II) chronic pain; Nyloxin and Nyloxin Extra Strength, stronger versions of Cobroxin, and Pet Pain-Away, an over-the-counter pain reliever designed to treat pain in cats and dogs. It has developed two drug candidates: RPI-78M, to treat neurological diseases and autoimmune diseases, and RPI-MN, to treat viral diseases.